Compare KNX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNX | GKOS |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.3B |
| IPO Year | 2010 | 2015 |
| Metric | KNX | GKOS |
|---|---|---|
| Price | $61.70 | $120.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 14 |
| Target Price | $59.94 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 3.1M | 765.7K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | ★ 0.36 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $7,469,689,000.00 | $383,481,000.00 |
| Revenue This Year | $5.92 | $23.29 |
| Revenue Next Year | $7.91 | $27.74 |
| P/E Ratio | $150.49 | ★ N/A |
| Revenue Growth | 0.80 | ★ 21.85 |
| 52 Week Low | $36.69 | $73.16 |
| 52 Week High | $62.20 | $130.69 |
| Indicator | KNX | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.30 | 54.83 |
| Support Level | $58.74 | $103.55 |
| Resistance Level | $60.67 | $121.70 |
| Average True Range (ATR) | 2.05 | 5.41 |
| MACD | -0.15 | 0.19 |
| Stochastic Oscillator | 69.84 | 83.01 |
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.